April 26, 2018 / 11:38 AM / 3 months ago

BRIEF-Axsome Therapeutics Says Independent Committee Recommends Continuation Of Depression Trial

April 26 (Reuters) - Axsome Therapeutics Inc:

* AXSOME THERAPEUTICS ANNOUNCES POSITIVE OUTCOME OF INTERIM ANALYSIS OF STRIDE-1 PHASE 3 TRIAL OF AXS-05 IN TREATMENT RESISTANT DEPRESSION

* AXSOME THERAPEUTICS INC - SECOND INTERIM ANALYSIS ANTICIPATED SECOND HALF OF 2018 FOR EFFICACY

* AXSOME THERAPEUTICS INC - INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDS TRIAL CONTINUATION

* AXSOME THERAPEUTICS INC - IDMC ALSO REVIEWED AVAILABLE SAFETY INFORMATION FROM STUDY AND INDICATED AXS-05 APPEARED SAFE AND WELL-TOLERATED Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below